Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENOV Enovis	$31.97 +6.7%	$33.03	$28.83 ▼ $49.83	$1.83B	1.72	844,703 shs	1.27 million shs
GKOS Glaukos	$100.20 +3.5%	$93.98	$77.10 ▼ $163.71	$5.73B	0.8	735,607 shs	545,646 shs
IRTC iRhythm Technologies	$153.65 +1.8%	$132.19	$55.92 ▼ $154.46	$4.90B	1.4	480,199 shs	469,238 shs
NARI Inari Medical	$79.97	$79.97	$39.76 ▼ $79.99	$4.68B	1.02	1.39 million shs	N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENOV Enovis	-0.41%	-6.96%	-5.07%	-23.82%	-33.45%
GKOS Glaukos	-3.51%	-3.51%	+0.60%	-9.29%	-14.35%
IRTC iRhythm Technologies	+3.57%	+4.24%	+5.79%	+41.60%	+46.52%
NARI Inari Medical	0.00%	0.00%	0.00%	0.00%	+73.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENOV Enovis	2.9602 of 5 stars	3.4	2.0	0.0	2.2	1.7	1.9
GKOS Glaukos	4.504 of 5 stars	4.4	2.0	4.4	2.1	2.5	0.6
IRTC iRhythm Technologies	1.409 of 5 stars	2.5	3.0	0.0	2.7	0.0	0.6
NARI Inari Medical	0.2844 of 5 stars	1.1	0.0	0.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENOV Enovis	2.80	Moderate Buy	$58.00	81.45% Upside
GKOS Glaukos	2.75	Moderate Buy	$134.67	34.40% Upside
IRTC iRhythm Technologies	2.90	Moderate Buy	$138.60	-9.79% Downside
NARI Inari Medical	2.14	Hold	$69.22	-13.44% Downside

Current Analyst Ratings Breakdown

Latest ENOV, GKOS, NARI, and IRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $160.00
5/22/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $167.00
5/14/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
5/9/2025	ENOV Enovis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$62.00 ➝ $55.00
5/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $57.00
5/6/2025	GKOS Glaukos	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$110.00 ➝ $72.00
5/2/2025	GKOS Glaukos	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $115.00
5/2/2025	IRTC iRhythm Technologies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$152.00 ➝ $139.00
5/2/2025	IRTC iRhythm Technologies	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$133.00 ➝ $150.00
5/2/2025	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$104.00 ➝ $130.00
5/2/2025	IRTC iRhythm Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$138.00 ➝ $151.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENOV Enovis	$2.11B	0.87	$20.36 per share	1.57	$45.10 per share	0.71
GKOS Glaukos	$383.48M	14.93	N/A	N/A	$13.91 per share	7.20
IRTC iRhythm Technologies	$591.84M	8.29	N/A	N/A	$2.90 per share	52.98
NARI Inari Medical	$493.63M	9.48	$0.09 per share	906.95	$8.07 per share	9.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENOV Enovis	-$825.49M	-$13.95	N/A	10.02	N/A	-37.65%	5.99%	3.44%	8/6/2025 (Estimated)
GKOS Glaukos	-$146.37M	-$2.37	N/A	N/A	N/A	-31.40%	-10.66%	-8.06%	7/30/2025 (Estimated)
IRTC iRhythm Technologies	-$113.29M	-$3.14	N/A	N/A	N/A	-15.90%	-101.04%	-9.55%	7/30/2025 (Estimated)
NARI Inari Medical	-$1.64M	-$1.35	N/A	727.00	N/A	-13.68%	-10.09%	-6.60%	N/A

Latest ENOV, GKOS, NARI, and IRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million
4/30/2025	Q1 2025	GKOS Glaukos	-$0.33	-$0.22	+$0.11	-$0.32	$102.78 million	$106.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENOV Enovis	N/A	N/A	N/A	N/A	N/A
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
NARI Inari Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENOV Enovis	0.52	2.55	1.32
GKOS Glaukos	0.09	6.49	5.62
IRTC iRhythm Technologies	7.47	5.71	5.58
NARI Inari Medical	N/A	1.77	1.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENOV Enovis	98.45%
GKOS Glaukos	99.04%
IRTC iRhythm Technologies	N/A
NARI Inari Medical	90.98%

Insider Ownership

Company	Insider Ownership
ENOV Enovis	2.70%
GKOS Glaukos	6.40%
IRTC iRhythm Technologies	0.68%
NARI Inari Medical	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENOV Enovis	7,367	57.12 million	55.58 million	Optionable
GKOS Glaukos	780	57.14 million	53.48 million	Optionable
IRTC iRhythm Technologies	2,000	31.92 million	31.71 million	Optionable
NARI Inari Medical	800	58.54 million	52.34 million	Optionable

ENOV, GKOS, NARI, and IRTC Headlines

Recent News About These Companies

Route 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of Directors

June 18, 2025 | finance.yahoo.com

American Century Small Cap Growth Fund Q1 2025 Commentary

June 11, 2025 | seekingalpha.com

Thrombectomy system removes clots, improves quality of life for patients with PE

May 20, 2025 | healio.com

The top nitinol cardiac medtech news of 2025 (so far)

May 13, 2025 | medicaldesignandoutsourcing.com

Stryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPS

May 2, 2025 | msn.com

Expert Testimony Supporting POPR Can Be An Effective Strategy

April 21, 2025 | jdsupra.com

Volta Medical Appoints Bill Hoffman as Executive Chairman of the Board of Directors

April 8, 2025 | finance.yahoo.com

8 spine, orthopedic acquisitions in Q1

March 27, 2025 | beckersspine.com

Okami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery Catheter

March 26, 2025 | finance.yahoo.com

How Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?

March 25, 2025 | kalkinemedia.com

If You Could Only Hold 3 Investments for Life, Consider These (NARI)

March 10, 2025 | marketbeat.com

Stryker’s Inari Medical Launches Artix Thrombectomy System

March 7, 2025 | evtoday.com

Stryker’s Inari Medical launches Artex thrombectomy system

March 7, 2025 | massdevice.com

Inari Medical introduces thrombectomy system for arterial thrombus cases

March 7, 2025 | msn.com

Inari Medical acquisition could provide Stryker with foothold in peripheral vascular market

February 28, 2025 | expresshealthcare.in

Wearable defibrillator maker Kestra Medical plots $150M IPO

February 26, 2025 | fiercebiotech.com

Stryker grows cardiovascular division with Inari Medical acquisition

February 24, 2025 | medicaldevice-network.com

Stryker Completes Acquisition of Inari

February 20, 2025 | evtoday.com

Stryker concludes Inari Medical acquisition for $4.9bn

February 20, 2025 | finance.yahoo.com

Stryker completes Inari Medical acquisition

February 20, 2025 | beckersspine.com

Inari Medical, Inc. (NARI): the Best Performing Healthcare Stock So Far in 2025

February 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares
Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes
By Gabriel Osorio-Mazilli | June 9, 2025
View Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes

ENOV, GKOS, NARI, and IRTC Company Descriptions

Enovis NYSE:ENOV

$31.96 +2.01 (+6.69%)

Closing price 03:59 PM Eastern

Extended Trading

$32.47 +0.50 (+1.58%)

As of 04:21 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Glaukos NYSE:GKOS

$100.20 +3.40 (+3.51%)

Closing price 03:59 PM Eastern

Extended Trading

$100.22 +0.02 (+0.02%)

As of 04:04 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

iRhythm Technologies NASDAQ:IRTC

$153.65 +2.70 (+1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$153.58 -0.06 (-0.04%)

As of 04:31 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Inari Medical NASDAQ:NARI

$79.97 0.00 (0.00%)

As of 02/19/2025

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time